Новое в консервативной терапии больных гиперплазией предстательной железы
Новое в консервативной терапии больных гиперплазией предстательной железы
Аляев Ю.Г., Винаров А.З., Локшин К.Л., Спивак Л.Г. Новое в консервативной терапии больных гиперплазией предстательной железы. Consilium Medicum. 2008; 10 (2): 45–48.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Huggins C, Steven R. The effect of castration on benign hypertrophy of the prostate in man. J Urol 1940; 43: 705.
2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293.
3. Wilson JD, Walker JD. The conversion of testosterone to b-androstan-17b-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest 1969; 48: 371–9.
4. Peterson RE, Imperato-McGinley J, Gauier T et al. Male pseudohermaphroditism due to steroid. Am J Med 1997; 62: 170–91.
5. Imperato-McGinley J, Peterson RE, Gauier T et al. Androgens and the evolution of male – gender identity among male pseudohermaphrodites with 5a-reductase deficiency. New Engl J Med 1979; 300: 1233–7.
6. Imperato-McGinley J, Gauier T, Zirinsky TH et al. Prostate visualization studies in male homozygous and heterozygous for 5a-reductase deficiency. J Clin Endocrinol Metab 1992; 75: 1022–6.
7. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185–91.
8. Gisleskog PO, Herman D, Hammarlund-Udenaes M et al. A model of the turnover of dihydrotestosterone in the presence of the irreversible 5a-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998; 64: 636–47.
9. Bramson HN, Hermann D, Batchelor KW et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496–502.
10. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5a-reductase types I and II (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–41.
11. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179–84.
12. McConnel JD, Wilson JD, Georges FW et al. Finasteride, an inhibitor of 5a-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–8.
13. Debruyne F, Barkin J, van Erps P et al. ARIA3001, ARIA3002, ARIB3001 study investigators. Efficacy and safety of along term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004, 46: 488–94.
14. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349 (25): 2387–98.
15. Roehrborn CG, Siami P, Barkin J et al. The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. J Urol 2008; 179: 616–21.
2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293.
3. Wilson JD, Walker JD. The conversion of testosterone to b-androstan-17b-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest 1969; 48: 371–9.
4. Peterson RE, Imperato-McGinley J, Gauier T et al. Male pseudohermaphroditism due to steroid. Am J Med 1997; 62: 170–91.
5. Imperato-McGinley J, Peterson RE, Gauier T et al. Androgens and the evolution of male – gender identity among male pseudohermaphrodites with 5a-reductase deficiency. New Engl J Med 1979; 300: 1233–7.
6. Imperato-McGinley J, Gauier T, Zirinsky TH et al. Prostate visualization studies in male homozygous and heterozygous for 5a-reductase deficiency. J Clin Endocrinol Metab 1992; 75: 1022–6.
7. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185–91.
8. Gisleskog PO, Herman D, Hammarlund-Udenaes M et al. A model of the turnover of dihydrotestosterone in the presence of the irreversible 5a-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998; 64: 636–47.
9. Bramson HN, Hermann D, Batchelor KW et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496–502.
10. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5a-reductase types I and II (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–41.
11. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179–84.
12. McConnel JD, Wilson JD, Georges FW et al. Finasteride, an inhibitor of 5a-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–8.
13. Debruyne F, Barkin J, van Erps P et al. ARIA3001, ARIA3002, ARIB3001 study investigators. Efficacy and safety of along term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004, 46: 488–94.
14. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349 (25): 2387–98.
15. Roehrborn CG, Siami P, Barkin J et al. The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. J Urol 2008; 179: 616–21.
Авторы
Ю.Г.Аляев, А.З.Винаров, К.Л.Локшин, Л.Г.Спивак
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.